Astria Therapeutics, Inc. (ATXS) Misses Q2 EPS by 8c

Astria Therapeutics, Inc. (NASDAQ: ATXS) reported Q2 EPS of ($0.57), $0.08 worse than the analyst estimate of ($0.49).

For earnings history and earnings-related data on Astria Therapeutics, Inc. (ATXS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• iMetal Resources closes $3M private placement with McFarlane Lake